Cysteine peptide-enabled antibodies
AssigneeCity of Hope
InventorsJohn C. Williams, Krzysztof Bzymek, Yuelong Ma, David Horne, Jeremy King
Life of this patent
Estimating the term…
Abstract
Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments covalently linked to a peptide compound through a disulfide linkage. The disulfide linkage is between a cysteine in the Fab region of the antibody or fragment thereof and a thiol moiety of a side chain amino acid of the peptide compound. The covalently formed complexes including provided herein form highly stable and versatile drug delivery and diagnostic compositions.
Claims65
A covalent complex comprising:
- (i) an antigen binding domain comprising:
- (1) a central hole enclosed by the heavy chain variable (VH) region, the light chain variable (VL) region, the heavy chain constant (CH1) region and the light chain constant (CL) region of said antigen binding domain between a first cavity and a second cavity;
- and
- (2) a non-CDR peptide binding region comprising:
- (a) said first cavity lined by a first set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain;
- (b) said second cavity lined by a second set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain;
- and
- (c) a hole region enclosing said hole between said first cavity and said second cavity, said hole region lined by a third set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain;
- wherein said non-CDR peptide binding region comprises a first cysteine;
- and
- (ii) a peptide compound comprising a thiol side chain amino acid covalently bound to said antigen binding domain through a disulfide linkage between said first cysteine and said thiol side chain amino acid.
(canceled)
-9. (canceled)
-13. (canceled)
(canceled)
-21. (canceled)
-24. (canceled)
(canceled)
-35. (canceled)
-45. (canceled)
-51. (canceled)
-55. (canceled)
-59. (canceled)
-74. (canceled)
A peptide compound of formula:
- R1—X0-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-R2 (I)
- wherein:
- X0 is Ser or null;
- X1 is Ser, Cys, Gly, β-alanine, diaminopropionic acid, β-azidoalanine, or null;
- X2 is Gln or null;
- X3 is Phe, Tyr, β,β′-diphenyl-Ala, His, Asp, 2-bromo-L-phenylalanine, 3-bromo-L-phenylalanine, 4-bromo-L-phenylalanine, Asn, Gln, a modified Phe, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
- X4 is Asp or Asn;
- X5 is Leu, β,β′-diphenyl-Ala, Phe, Trp, Tyr, a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
- X6 is Cys or Ser;
- X7 is Cys, Thr, or Ser;
- X8 is protected Arg, Arg, Ala, or an amino acid comprising a side chain of the formula -L3A-L3B-R3, wherein L3A is a bond, —O—, —S—, —C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—,substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene, L3B is a chemical linker and R3 is a steric hindering chemical moiety;
- X9 is Cys, Arg or Ala;
- X10 is Leu, Gln, Glu, β,β′-diphenyl-Ala, Phe, Trp, Tyr;
- a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
- X11 is Cys, Gln, Lys or Arg;
- X12 is Ser, Cys, Gly, 7-aminoheptanoic acid, β-alanine, diaminopropionic acid, propargylglycine, isoaspartic acid, or null;
- R1 is null, -L10A-L10B-R10, amino acid peptide sequence optionally substituted with -L10A-L10B-R10;
- R2 is null, -L20A-L20B-R20, an amino acid peptide sequence optionally substituted with -L20A-L20B-R20;
- wherein
- L10A, L10B, R20A, L20B are independently a bond, a peptidyl linker, —O—, —S—,
- —C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene;
- R10 and R20 are independently a reactive moiety, a diagnostic moiety, a therapeutic moiety or a detectable moiety;
- wherein X1 and X12 are optionally joined together to form a cyclic peptidyl moiety;
- and
- wherein R1 and X11 are optionally joined together to form a cyclic peptidyl moiety.
-83. (canceled)
-87. (canceled)
-93. (canceled)
-102. (canceled)
A peptide compound of formula:
- R1—X0-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-R2 (II)
- wherein:
- X0 is Ser or null;
- X1 is Ser, Cys, Gly, β-alanine, diaminopropionic acid, β-azidoalanine, or null;
- X2 is Gln or null;
- X3 is Phe, Tyr, β,β′-diphenyl-Ala, His, Asp, 2-bromo-L-phenylalanine, 3-bromo-L-phenylalanine, 4-bromo-L-phenylalanine, Asn, Gln, a modified Phe, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
- X4 is Asp or Asn;
- X5 is Leu, β,β′-diphenyl-Ala, Phe, Trp, Tyr, a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
- X6 is Ser;
- X7 is Cys, Thr, or Ser;
- X8 is Arg, Ala, or an amino acid comprising a side chain of the formula -L3A-L3B-R3, wherein L3A is a bond, —O—, —S—, —C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene, L3B is a chemical linker and R3 is a steric hindering chemical moiety;
- X9 is Cys, Arg or Ala;
- X10 is Leu, Gln, Glu, β,β′-diphenyl-Ala, Phe, Trp, Tyr;
- a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
- X11 is Cys, Gln, Lys or Arg;
- X12 is Ser, Cys, Gly, 7-aminoheptanoic acid, β-alanine, diaminopropionic acid, propargylglycine, isoaspartic acid, or null;
- X13 is Gly or Ser;
- X14 and X15 are independently Gly, Ser, Ala, or Cys;
- R1 is null, -L10A-L10B-R10, an amino acid peptide sequence optionally substituted with -L10A-L10B-R10;
- R2 is null, -L20A-L20B-R20, an amino acid peptide sequence optionally substituted with -L20A-L20B-R20;
- wherein
- L10A, L10B, L20A, L20B are independently a bond, a peptidyl linker, —O—, —S—,
- —C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene;
- R10 and R20 are independently a reactive moiety, a diagnostic moiety, a therapeutic moiety or a detectable moiety;
- and
- wherein X1 and X12 are optionally joined together to form a cyclic peptidyl moiety.
-116. (canceled)
An antigen binding domain comprising:
- (1) a central hole enclosed by the heavy chain variable (VH) region, the light chain variable (VL) region, the heavy chain constant (CH1) region and the light chain constant (CL) region of said antigen binding domain between a first cavity and a second cavity;
- and
- (2) a non-CDR peptide binding region comprising:
- (a) said first cavity lined by a first set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain, wherein said first set of amino acid residues comprises a cysteine at a position corresponding to Kabat position 102, 142 or 143 of said VL region;
- (b) said second cavity lined by a second set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain, wherein said second set of amino acid residues comprises a cysteine at a position corresponding to Kabat position 208 or 158 of said VH region;
- or
- (c) a hole region enclosing said hole between said first cavity and said second cavity, said hole region lined by a third set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain, wherein said third set of amino acid residues comprises a cysteine at a position corresponding to Kabat position 174 or 175 of said VH region.
-128. (canceled)
Dependencies are inferred from the claim text.